Summary:
- This article discusses a new drug called MN-002 that is being developed by Medicinova, a pharmaceutical company, to treat atherosclerosis, a condition where plaque builds up in the arteries.
- The article reports on a peer-reviewed study that found MN-002 was effective in reducing plaque buildup and improving blood flow in animal models, suggesting it could potentially redefine how atherosclerosis is treated.
- The article also mentions that MN-002 is currently in clinical trials, and if successful, it could provide a new and more effective treatment option for people with atherosclerosis, which is a leading cause of heart attacks and strokes.